Merck & Co. Inc. (MRK)

81.39
NYSE : Health Technology
Prev Close 82.69
Day Low/High 81.15 / 82.82
52 Wk Low/High 62.01 / 87.07
Avg Volume 10.49M
Exchange NYSE
Shares Outstanding 2.57B
Market Cap 212.90B
EPS 2.30
P/E Ratio 48.08
Div & Yield 2.20 (2.60%)
Cramer: Is the Market Playing 'The Price Is Wrong'?

Cramer: Is the Market Playing 'The Price Is Wrong'?

These may be uncharted waters, but they're not necessarily expensive.

Cramer: Buyers for Bristol-Myers Are Few and Far Between

Cramer: Buyers for Bristol-Myers Are Few and Far Between

Icahn may have a tough time finding interest in this behemoth.

Health Care ETF Has Been Ailing

Health Care ETF Has Been Ailing

You might want to review your holdings in the sector.

Snapchat's Parent Prices IPO at Low End of Expectations

Snapchat's Parent Prices IPO at Low End of Expectations

Snap Inc. is preparing for the biggest technology IPO since Alibaba in 2014.

Merck target cut at BMO

Cramer: Here's the Reason for Allergan's Remarkable Run

Cramer: Here's the Reason for Allergan's Remarkable Run

Static doesn't work in this industry. Pipelines work.

Cramer: Allergan Is the New Pharma Growth Stock

Cramer: Allergan Is the New Pharma Growth Stock

Jim Cramer compares Allergan's growth to other pharma stocks.

Streamlined FDA Approval Process Would Boost Drug Makers

Streamlined FDA Approval Process Would Boost Drug Makers

Would get drugs to market faster and possibly more cheaply.

Novice Trade: AbbVie

Novice Trade: AbbVie

Getting FDA to streamline its approval process would boost drug makers.

7 Things to Watch in Biotech Now

7 Things to Watch in Biotech Now

M&A, drug approvals and Trump are all on my watch list.

Synergy Pharmaceuticals Consolidating Recent Gains

The market continues to be in rally mode as everyone watches the presidential inauguration ceremonies. Biotech is not participating in the rally. Bristol Myers-Squibb is one reason the sector is not participating, as its key oncology drug Opdivo wil...

Setback for Bristol-Myers on Lung Cancer Treatment Drugs

Setback for Bristol-Myers on Lung Cancer Treatment Drugs

Bristol-Myers Squibb suffers a setback in immunotherapy treatment for newly diagnosed lung cancer.

My Takeaways and Observations (Early Edition)

I had my most active day of the year trading. It was also my most profitable.   Regardless of one's market view, I continue to see more opportunities on the trading side vs. the investing side in the months ahead.   I started the day with a story re...

Merck upgraded at Piper

Merck upgraded at Morgan Stanley

Cramer: Trump Doesn't Seem to Care About the Trump Rally

Cramer: Trump Doesn't Seem to Care About the Trump Rally

He's never really been a stock market guy anyway.

Midday Report: Biotech Stocks Tumble on Trump's Talk; Stocks Fluctuate

Midday Report: Biotech Stocks Tumble on Trump's Talk; Stocks Fluctuate

U.S. stocks fluctuated Wednesday after President-elect Trump targets the biotech industry in his first press conference since July.

Cramer: What Happened to the Pajama Traders?

Cramer: What Happened to the Pajama Traders?

The terror that the futures struck, rightly or wrongly, has disappeared.

My Takeaways and Observations

"I don't feel Tuesday...Tuesday has no feel." -- Seinfeld  I started the day with some food for thought -- on the changing channels of retail distribution. In this opener please pay some attention to not only the ramifications for retail stocks but ...

4 Biotech Names That Could Be M&A Targets

4 Biotech Names That Could Be M&A Targets

Animal health and oncology deal activity is heating up in 2017.

My Takeaways and Observations

I wrote in my 15 Surprises for 2017 that Mr. Market may make a yearly high in the first two weeks of January. We are now wrapping up that period -- and I plan to expand my relatively small short exposure.   In other words, I am sticking to my script...

Cramer: A Dozen Stocks in the Dow That Can Regain Their Former Glory

Cramer: A Dozen Stocks in the Dow That Can Regain Their Former Glory

You have to think that if these stocks were so high once, then it's likely they will be again.

3 Takeover Candidates in the Drug Space

3 Takeover Candidates in the Drug Space

Potential acquirers include Gilead Sciences, Johnson & Johnson, Pfizer, Merck and Novartis.

Cramer: Too Few Stocks Are Doing Too Much in Dow's Run to 20,000

Cramer: Too Few Stocks Are Doing Too Much in Dow's Run to 20,000

Disney and Goldman are doing a lot of the heavy lifting.

3 Takeover Candidates in the Drug Space

3 Takeover Candidates in the Drug Space

Potential acquirers include Gilead Sciences, Johnson & Johnson, Pfizer, Merck and Novartis.

Watch Beaten-Down Drug Companies, Hospitals in 2017

Watch Beaten-Down Drug Companies, Hospitals in 2017

There may be some diamonds-in-the-rough among pharmaceutical consolidators and hospital chains.

These 2 'Dogs of Dow' Are Set to Be Unleashed

These 2 'Dogs of Dow' Are Set to Be Unleashed

The popular dividend strategy has been a lucrative investment in 2016, but what's in store for 2017?

Biotech Poised for Rebound

Biotech Poised for Rebound

If M&A picks up and Trump doesn't tweet about excessively high drug prices, there should be bounce.

Biotech Poised for Rebound

Biotech Poised for Rebound

If M&A picks up and Trump doesn't tweet about excessively high drug prices, there should be bounce.

Bed Bath & Beyond Needs Fresh Thinking; Time for an Activist Raid

Bed Bath & Beyond Needs Fresh Thinking; Time for an Activist Raid

There is a dearth of retail experience on its board during a period of major industry disruption.